Alloy Therapeutics nabs a $75M series C to sow more seeds into the biotech ecosystem

Alloy Therapeutics has raised $75 million to help grow its own drug development platform and help the life sciences community seek out and trial more drugs.

The Boston-based drug discovery company uses its ATX-Gx in vivo human antibody discovery platform, currently employed by more than 70 life sciences teams in biopharma and academia, and its setup to “democratize” research by making access easier and cheaper.